Method of screening for sensitivity to kinase inhibitor therapy
Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of a TKI on a weekly or semi-weekly basis. Alternate embodiments of the present invention include a diagnostic method for assessing an individual's probability of being resistant to TKI therapy, based upon an expression level of epithelial membrane protein-1 (EMP-1); one of the genes believed to be responsible for TKI resistance. The methods of the present invention may be particularly useful in the treatment of lung, breast, prostate, ovarian, brain and colon cancers. The methods of the present invention may be effective in blocking the HER-2 kinase domain either in addition to or in lieu of blocking the EGFR kinase domain.
1. A method of screening an individual with prostate or lung cancer for sensitivity to gefitinib therapy, comprising:
obtaining a tumor sample from the individual with prostate or lung cancer;
contacting the tumor sample with a nucleic acid probe for epithelial membrane protein 1 (EMP-1);
examining an expression level of EMP-1 mRNA the tumor sample;
caring the expression level of EMP-1 mRNA of the tumor sample to an expression level of EMP-1 mRNA of a gefitinib sensitive prostate or lung tumor; and
determining the prostate or lung cancer is resistant or non-responsive to conventional gefitinib therapy when the expression level of EMP-1 mRNA of the tumor sample is 20-fold or higher than the expression level of EMP-1 mRNA of the gefitinib sensitive prostate or lung tumor.
2. The method of claim 1 , wherein the individual has prostate cancer.
3. The method of claim 1 , wherein the individual has lung cancer.
4. The method of claim 1 , wherein the nucleic acid probe is on a gene chip.